Silencing of FABP1 ameliorates hepatic steatosis, inflammation, and oxidative stress in mice with nonalcoholic fatty liver disease

Nonalcoholic fatty liver disease (NAFLD) is increasing in prevalence worldwide and has been identified as a risk factor for cirrhosis and hepatocellular carcinoma. However, there is no effective pharmacologic treatment for NAFLD. FABP1 is a liver‐specific fatty acid‐binding protein (FABP) that plays...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:FEBS Open Bio
Egile Nagusiak: Mukai, Takako, Egawa, Miki, Takeuchi, Tamaki, Yamashita, Hitoshi, Kusudo, Tatsuya
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: John Wiley and Sons Inc. 2017
Gaiak:
Research Articles
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5494302/
https://ncbi.nlm.nih.gov/pubmed/28680813
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/2211-5463.12240
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak